SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 05/14/2019
Entire Document
 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As previously announced, on April 30, 2019, Pernix Therapeutics Holdings, Inc. (the “Company”) and certain of its subsidiaries (together, the “Sellers”) completed the sale of substantially all of their assets (the “Asset Sale”) to Currax Holdings LLC (f/k/a Phoenix Top Holdings LLC), an entity formed by affiliates of Highbridge Capital Management (in such capacity, the “Purchaser”), pursuant to the Amended and Restated Asset Purchase Agreement, dated as of April 15, 2019 among the Sellers and the Purchaser.

 

Following consummation of the Asset Sale, on May 8, 2019, Dennis H. Langer, a member of the Board of Directors of the Company (the “Board”), resigned from the Board, effective May 1, 2019.

 

Following consummation of the Asset Sale, on May 9, 2019, Douglas J. Swirsky and Kinyip Gabriel Leung, members of the Board, resigned from the Board, effective May 1, 2019.

 

Following consummation of the Asset Sale, Kenneth R. Pina resigned from his position as Senior Vice President, Chief Legal  & Compliance Officer and Corporate Secretary of the Company, effective May 1, 2019.